학술논문
Efficacy and safety of elbasvir and grazoprevir for chronic hepatitis C patients with chronic kidney disease / 慢性腎臓病合併C型慢性肝炎に対するエルバスビル・グラゾプレビル療法の有効性と安全性
Document Type
Journal Article
Author
Akihiro Deguchi; Akihito Tsubota; Akio Moriya; Chikara Ogawa; Chisa Kondo; Etsuko Iio; Hidenori Toyoda; Hiroshi Abe; Joji Tani; Keizo Kato; Koichi Takaguchi; Makoto Oryu; Masanori Atsukawa; Norio Itokawa; Noritomo Shimada; Shigeru Mikami; Taeang Arai; Takashi Kumada; Takeshi Fukuda; Tomomi Okubo; Toru Asano; Tsutomu Masaki; Yasuhito Tanaka; Yoshimichi Chuganji; Yuji Osada; 三上 繁; 出口 章広; 加藤 慶三; 厚川 正則; 坪田 昭人; 大久保 知美; 守屋 昭男; 安部 宏; 小川 力; 尾立 磨琴; 島田 紀朋; 忠願寺 義通; 新井 泰央; 正木 勉; 浅野 徹; 熊田 卓; 田中 靖人; 福田 健; 糸川 典夫; 谷 丈二; 豊田 秀徳; 近藤 千紗; 長田 祐二; 飯尾 悦子; 高口 浩一
Source
肝臓 / Kanzo. 2017, 58(12):678
Subject
Language
Japanese
ISSN
0451-4203
1881-3593
1881-3593
Abstract
The aim of this retrospective multicenter study was to clarify efficacy and safety of Elbasvir/Grazoprevir for chronic hepatitis C patients with chronic kidney disease (CKD). Forty-five patients with CKD were administered Elbasvir/Grazoprevir and subjected to this analysis. Overall sustained virologic response 12 rates in CKD patients were 95.6%. The sustained virologic response 4 and 12 rates were 92.9% and 92.9% in CKD G3 patients, 100% and 100% in G4 patients and 100% and 100% in G5 patients including 10 dialysis patients, respectively. The frequency of adverse event did not increase in the patients with CKD. This study suggests that Elbasvir/Grazoprevir therapy is effective and safe for genotype 1b chronic hepatitis C patients with CKD.